If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

RVNC Insider Trading (Revance Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.10%

Insider Buying (Last 12 Months): $1,049,636.00

Insider Selling (Last 12 Months): $50,250.00

Revance Therapeutics Insider Trading History Chart

Revance Therapeutics Share Price & Price History

^$22.32

▲ +0.2 (0.90%)

As of 08/16/2022 01:00 AM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

Revance Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2021	Angus C. Russell	Director	Buy	6,400	$15.74	$100,736.00
12/3/2021	Aubrey Rankin	Insider	Buy	30,000	$14.43	$432,900.00
11/29/2021	Mark J. Foley	CEO	Buy	40,000	$12.90	$516,000.00
9/27/2021	Dwight Moxie	SVP	Sell	1,675	$30.00	$50,250.00
8/16/2021	Aubrey Rankin	Insider	Sell	9,364	$26.34	$246,647.76
7/28/2021	Aubrey Rankin	Insider	Sell	54,332	$30.06	$1,633,219.92	79,776
7/26/2021	Aubrey Rankin	Insider	Sell	55,382	$29.72	$1,645,953.04	79,776
4/5/2021	Aubrey Rankin	Insider	Sell	2	$28.28	$56.56	79,776
3/4/2021	Aubrey Rankin	Insider	Sell	33,119	$25.43	$842,216.17	79,776
2/1/2021	Aubrey Rankin	Insider	Sell	33,119	$25.95	$859,438.05	67,871
11/30/2020	Aubrey Rankin	Insider	Sell	33,119	$23.85	$789,888.15	67,871
10/29/2020	Aubrey Rankin	Insider	Sell	33,119	$26.15	$866,061.85	67,871
9/28/2020	Aubrey Rankin	Insider	Sell	33,119	$26.18	$867,055.42	67,871

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for Revance Therapeutics (NASDAQ:RVNC)

79.94% of Revance Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Revance Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/16/2022	First Republic Investment Management Inc.	27,978	$0.39M	0.0%	-67.1%	0.038%
8/16/2022	Castleark Management LLC	129,313	$1.79M	0.1%	N/A	0.177%
8/16/2022	Prudential Financial Inc.	52,084	$0.72M	0.0%	-61.6%	0.071%
8/16/2022	Corton Capital Inc.	11,736	$0.16M	0.2%	N/A	0.016%
8/16/2022	Delphia USA Inc.	12,881	$0.18M	0.1%	N/A	0.018%
8/15/2022	Occudo Quantitative Strategies LP	43,769	$0.61M	0.0%	N/A	0.060%
8/15/2022	Palo Alto Investors LP	4,405,039	$60.88M	5.3%	-0.2%	6.026%
8/15/2022	State Street Corp	1,779,793	$24.60M	0.0%	+15.5%	2.435%
8/15/2022	PDT Partners LLC	110,690	$1.53M	0.1%	N/A	0.151%
8/15/2022	Point72 Hong Kong Ltd	6,656	$92K	0.0%	N/A	0.009%
8/15/2022	Cubist Systematic Strategies LLC	245,212	$3.39M	0.0%	+943.2%	0.335%
8/15/2022	Point72 Asset Management L.P.	605,574	$8.37M	0.0%	-23.0%	0.828%
8/15/2022	Millennium Management LLC	470,124	$6.50M	0.0%	+252.2%	0.643%
8/15/2022	Sei Investments Co.	72,977	$1M	0.0%	+3.8%	0.100%
8/15/2022	UBS Asset Management Americas Inc.	68,832	$0.95M	0.0%	+4.6%	0.094%
8/13/2022	Rothschild & Co. Asset Management US Inc.	216,470	$2.99M	0.0%	-2.7%	0.296%
8/13/2022	Teacher Retirement System of Texas	10,509	$0.15M	0.0%	-24.5%	0.014%
8/13/2022	American International Group Inc.	32,810	$0.45M	0.0%	-5.9%	0.045%
8/12/2022	Natixis	85,000	$1.18M	0.0%	N/A	0.117%
8/12/2022	Northern Trust Corp	678,300	$9.37M	0.0%	-4.0%	0.932%
8/12/2022	LPL Financial LLC	13,343	$0.18M	0.0%	+30.1%	0.018%
8/12/2022	Rafferty Asset Management LLC	12,793	$0.18M	0.0%	N/A	0.017%
8/12/2022	FMR LLC	1,214,318	$16.78M	0.0%	-1.4%	1.661%
8/12/2022	Essex Investment Management Co. LLC	63,588	$0.88M	0.1%	-1.4%	0.087%
8/12/2022	BNP Paribas Arbitrage SA	16,721	$0.23M	0.0%	+129.8%	0.023%
8/12/2022	Rhumbline Advisers	83,443	$1.15M	0.0%	+3.1%	0.115%
8/11/2022	Evolutionary Tree Capital Management LLC	134,188	$1.85M	2.0%	-23.9%	0.184%
8/11/2022	AlphaCrest Capital Management LLC	23,040	$0.32M	0.0%	N/A	0.032%
8/11/2022	DCF Advisers LLC	12,000	$0.17M	0.1%	N/A	0.016%
8/11/2022	UBS Group AG	86,909	$1.20M	0.0%	-2.6%	0.119%
8/10/2022	Principal Financial Group Inc.	18,893	$0.26M	0.0%	+47.0%	0.026%
8/10/2022	Inspire Investing LLC	15,540	$0.22M	0.0%	+27.1%	0.021%
8/8/2022	Walleye Capital LLC	464,970	$6.43M	0.2%	-8.1%	0.639%
8/8/2022	Rice Hall James & Associates LLC	1,085,340	$15M	0.7%	-2.4%	1.492%
8/8/2022	Keybank National Association OH	12,922	$0.18M	0.0%	N/A	0.018%
8/3/2022	Envestnet Asset Management Inc.	10,668	$0.15M	0.0%	-14.9%	0.015%
8/3/2022	DekaBank Deutsche Girozentrale	86,100	$1.22M	0.0%	+229.9%	0.118%
8/3/2022	Sciencast Management LP	11,209	$0.17M	0.0%	N/A	0.015%
8/2/2022	Carnegie Capital Asset Management LLC	9,800	$0.29M	0.0%	N/A	0.013%
8/2/2022	Jennison Associates LLC	1,755,703	$24.26M	0.0%	-28.1%	2.413%
8/1/2022	ProShare Advisors LLC	13,541	$0.19M	0.0%	-34.1%	0.019%
7/27/2022	Assenagon Asset Management S.A.	130,648	$1.81M	0.0%	+6.9%	0.180%
7/26/2022	Mirae Asset Global Investments Co. Ltd.	21,625	$0.30M	0.0%	N/A	0.030%
7/20/2022	Denali Advisors LLC	5,500	$76K	0.0%	-15.4%	0.008%
7/19/2022	Commonwealth Equity Services LLC	32,813	$0.45M	0.0%	+8.2%	0.045%
7/19/2022	Hennion & Walsh Asset Management Inc.	89,020	$1.23M	0.1%	-4.4%	0.122%
7/18/2022	Denali Advisors LLC	5,500	$76K	0.0%	-15.4%	0.008%
7/13/2022	Carnegie Capital Asset Management LLC	9,800	$0.29M	0.0%	N/A	0.013%
7/11/2022	Flaharty Asset Management LLC	17,452	$0.24M	0.0%	+12.9%	0.024%
6/30/2022	Amalgamated Bank	11,428	$0.22M	0.0%	-7.5%	0.016%
5/27/2022	Walleye Capital LLC	505,701	$9.86M	0.2%	+41.6%	0.695%
5/19/2022	Capital World Investors	3,350,000	$65.33M	0.0%	-9.8%	4.604%
5/18/2022	BNP Paribas Arbitrage SA	7,276	$0.14M	0.0%	-54.4%	0.010%
5/17/2022	Walleye Capital LLC	505,701	$9.86M	0.2%	+41.6%	0.695%
5/17/2022	Polar Capital Holdings Plc	2,456,497	$47.90M	0.2%	+8.7%	3.376%
5/17/2022	Ensign Peak Advisors Inc	21,800	$0.43M	0.0%	+64.8%	0.030%
5/17/2022	First Republic Investment Management Inc.	85,145	$1.66M	0.0%	-24.3%	0.117%
5/17/2022	Guggenheim Capital LLC	36,805	$0.72M	0.0%	+2.9%	0.051%
5/16/2022	California State Teachers Retirement System	88,547	$1.73M	0.0%	-7.8%	0.124%
5/16/2022	Goldman Sachs Group Inc.	656,556	$12.80M	0.0%	-18.5%	0.919%
5/16/2022	Palo Alto Investors LP	4,415,689	$86.11M	6.7%	+1.1%	6.182%
5/16/2022	State Street Corp	1,541,437	$30.06M	0.0%	-1.6%	2.158%
5/16/2022	Graham Capital Management L.P.	20,030	$0.39M	0.0%	N/A	0.028%
5/16/2022	Invesco Ltd.	218,346	$4.26M	0.0%	+454.3%	0.306%
5/16/2022	UBS Group AG	89,270	$1.74M	0.0%	+5.5%	0.125%
5/16/2022	Granahan Investment Management LLC	161,695	$3.15M	0.1%	-25.3%	0.226%
5/16/2022	Hsbc Holdings PLC	60,108	$1.17M	0.0%	+3.6%	0.084%
5/13/2022	Rhenman & Partners Asset Management AB	198,358	$3.87M	0.4%	N/A	0.278%
5/13/2022	Evolutionary Tree Capital Management LLC	176,336	$3.44M	2.4%	-29.0%	0.247%
5/13/2022	Northern Trust Corp	706,616	$13.78M	0.0%	-3.3%	0.989%
5/13/2022	Charles Schwab Investment Management Inc.	491,462	$9.58M	0.0%	+3.1%	0.688%
5/13/2022	First Trust Advisors LP	24,653	$0.48M	0.0%	-57.3%	0.035%
5/13/2022	Prudential Financial Inc.	135,754	$2.65M	0.0%	+63.4%	0.190%
5/13/2022	American International Group Inc.	34,851	$0.68M	0.0%	-6.6%	0.049%
5/13/2022	Vanguard Group Inc.	3,645,311	$71.08M	0.0%	+1.2%	5.103%
5/13/2022	Rothschild & Co. Asset Management US Inc.	222,408	$4.34M	0.1%	-23.1%	0.311%
5/13/2022	Sei Investments Co.	70,281	$1.37M	0.0%	-3.6%	0.098%
5/13/2022	Dimensional Fund Advisors LP	98,129	$1.91M	0.0%	-25.5%	0.137%
5/12/2022	Panagora Asset Management Inc.	49,123	$0.96M	0.0%	+358.8%	0.069%
5/12/2022	Metropolitan Life Insurance Co NY	4,774	$93K	0.0%	-71.8%	0.007%
5/12/2022	MetLife Investment Management LLC	39,127	$0.76M	0.0%	+53.8%	0.055%
5/12/2022	Citigroup Inc.	12,451	$0.24M	0.0%	-114.2%	0.017%
5/12/2022	HighTower Advisors LLC	1,233,140	$24.05M	0.1%	+27.4%	1.726%
5/11/2022	Bank of New York Mellon Corp	274,539	$5.35M	0.0%	-0.6%	0.384%
5/11/2022	Jennison Associates LLC	2,441,286	$47.61M	0.0%	+10.8%	3.418%
5/11/2022	GSA Capital Partners LLP	67,232	$1.31M	0.2%	N/A	0.094%
5/10/2022	ProShare Advisors LLC	20,556	$0.40M	0.0%	-19.2%	0.029%
5/10/2022	Mercer Global Advisors Inc. ADV	12,731	$0.25M	0.0%	-37.8%	0.018%
5/9/2022	Essex Investment Management Co. LLC	64,509	$1.26M	0.2%	-50.1%	0.090%
5/9/2022	Principal Financial Group Inc.	12,850	$0.25M	0.0%	+7.6%	0.018%
5/9/2022	Swiss National Bank	161,250	$3.14M	0.0%	+7.9%	0.226%
5/9/2022	Teacher Retirement System of Texas	13,921	$0.27M	0.0%	+7.6%	0.019%
5/6/2022	CIBC Asset Management Inc	470,819	$9.18M	0.0%	-5.5%	0.659%
5/5/2022	Rice Hall James & Associates LLC	1,112,325	$21.69M	0.9%	-0.1%	1.529%
5/4/2022	Advisor Group Holdings Inc.	2,838	$56K	0.0%	+60.6%	0.004%
5/4/2022	Prospera Financial Services Inc	6,272	$0.12M	0.0%	N/A	0.009%
5/4/2022	Commonwealth Equity Services LLC	30,313	$0.59M	0.0%	+22.7%	0.042%
5/4/2022	Envestnet Asset Management Inc.	12,543	$0.25M	0.0%	-38.2%	0.018%
5/3/2022	State of New Jersey Common Pension Fund D	200,094	$3.90M	0.0%	N/A	0.280%
4/28/2022	DekaBank Deutsche Girozentrale	26,100	$0.51M	0.0%	-7.4%	0.037%

Data available starting January 2016

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $22.32

$21.67

$22.71

50 Day Range

MA: $15.67

$11.52

$22.49

52 Week Range

Now: $22.32

$11.27

$30.00

Volume

631,090 shs

Average Volume

701,111 shs

Market Capitalization

$1.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Who are the company insiders with the largest holdings of Revance Therapeutics?: Revance Therapeutics' top insider investors include:
Aubrey Rankin (Insider)
Angus C Russell (Director)
Dwight Moxie (SVP)
Mark J Foley (CEO)
Learn More about top insider investors at Revance Therapeutics.
Who are the major institutional investors of Revance Therapeutics?: Revance Therapeutics' top institutional investors include:
Palo Alto Investors LP — 6.03%
State Street Corp — 2.43%
Jennison Associates LLC — 2.41%
FMR LLC — 1.66%
Rice Hall James & Associates LLC — 1.49%
Northern Trust Corp — 0.93%
Learn More about top institutional investors of Revance Therapeutics stock.
Which major investors are selling Revance Therapeutics stock?: During the last quarter, RVNC stock was sold by these institutional investors:
Jennison Associates LLC
Point72 Asset Management L.P.
Prudential Financial Inc.
First Republic Investment Management Inc.
Evolutionary Tree Capital Management LLC
Walleye Capital LLC
Northern Trust Corp
Citadel Advisors LLC
Which major investors are buying Revance Therapeutics stock?: During the previous quarter, RVNC stock was bought by institutional investors including:
Millennium Management LLC
State Street Corp
Cubist Systematic Strategies LLC
Castleark Management LLC
PDT Partners LLC
Group One Trading L.P.
Natixis
DekaBank Deutsche Girozentrale
Within the last year, these company insiders have bought Revance Therapeutics stock:
Aubrey Rankin (Insider)
Angus C Russell (Director)
Dwight Moxie (SVP)
Learn More investors buying Revance Therapeutics stock.